EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants

Rupak Shivakoti, Barbara Laughton, Jenna Mandell, Ana Barrios-Tascon, Reshma Rajendran, Richard Glashoff, Lars Bode, Grace Aldrovandi, Louise Kuhn

Advances in Nutrition · 2026-03 · 17 (3) · 100593

DOI: 10.1016/j.advnut.2026.100593 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advances in Nutrition, 2026-03. Verfasst von Rupak Shivakoti und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, United States. Electronic addre…. Hauptthemen laut MEDLINE: Oligosaccharides, Milk, Human, Infant Nutritional Physiological Phenomena, Dietary Supplements. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, University of California-San Diego.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human milk oligosaccharides (HMOs) are complex carbohydrates unique to human milk, and a wealth of observational and mechanistic studies indicate that HMOs are key to infant health by supporting gut microbiota and immune development. This review synthesizes evidence from randomized clinical trials evaluating whether supplementation with human-identical milk oligosaccharides (HiMOs), i.e., synthetic HMOs, in infants and young children improves health outcomes. We identified 12 randomized clinical trials: 8 in healthy infants, 3 in special populations of infants, and 1 in young children. We selected only trials with a randomized, parallel group design; most of the included trials also had an observational human milk-fed control group. The most widely evaluated HiMO was 2'-fucosyllactose used alone or in combination with other HiMOs. In some trials, other bioactive components were included in the control and/or intervention formula groups, complicating interpretation. All trials in healthy infants confirmed the noninferiority of HiMO-supplemented formula on growth and tolerability relative to control formula. Results were mixed with respect to reductions in morbidity, and all studies were underpowered for more severe morbidity outcomes. Stool microbiota and biomarkers of inflammation and gut function generally shifted in a direction closer to human milk-fed infants with HiMO intervention. Some growth improvements were noted in association with HiMO intervention in preterm infants and in infants with severe acute malnutrition. HiMO supplementation may be a promising intervention to improve child health, but due to the heterogeneity and limitations of the clinical trials that have been undertaken, many questions remain about the nature of the benefits and the specific populations who might benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligosaccharidesMilk, HumanInfant Nutritional Physiological PhenomenaDietary SupplementsHumansInfantRandomized Controlled Trials as TopicInfant FormulaGastrointestinal MicrobiomeInfant, NewbornTrisaccharidesFemalePrebioticsChild, Preschool

Stichwörter der Autor:innen

HMOHiMOsbreastfeedingbreastmilkchildrenhuman milk oligosaccharideshuman-identical milk oligosaccharidesinfectionmicrobiomemicrobiotaprebioticsrandomized trials

Substanzen

OligosaccharidesTrisaccharides2'-fucosyllactosePrebiotics

Autor:innen und Institutionen

  • Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, United States. Electronic address: rs3895@cumc.columbia.edu.
  • Department of Paediatrics and Child Health, Stellenbosch University, Stellenbosch, South Africa.
  • Department of Epidemiology, Mailman School of Public Health, Columbia University Irving Medical Center, New York, NY, United States.
  • Gertrude H Sergievsky Center, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, NY, United States.
  • Division of Medical Microbiology and Immunology, Department of Pathology, National Health Laboratory Service, Stellenbosch University, Cape Town, South Africa.
  • Department of Pediatrics, Larsson-Rosenquist Foundation Mother-Milk-Infant Center of Research Excellence Human Milk Institute, University of California San Diego, La Jolla, CA, United States.

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • University of California-San Diego
  • National Institute of Child Health and Human Development

Zitieren

APA

Shivakoti, R., Laughton, B., Mandell, J., Barrios-Tascon, A., Rajendran, R., Glashoff, R., Bode, L., Aldrovandi, G., & Kuhn, L. (2026). Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants. Advances in Nutrition, 17(3), 100593. https://doi.org/10.1016/j.advnut.2026.100593

Vancouver

Shivakoti R, Laughton B, Mandell J, Barrios-Tascon A, Rajendran R, Glashoff R, et al. Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants. Advances in Nutrition. 2026;17(3):100593. doi:10.1016/j.advnut.2026.100593

BibTeX
@article{Shivakoti2026,
  author = {Shivakoti, Rupak and Laughton, Barbara and Mandell, Jenna and Barrios-Tascon, Ana and Rajendran, Reshma and Glashoff, Richard and Bode, Lars and Aldrovandi, Grace and Kuhn, Louise},
  title = {Limited Evidence of Benefits from Clinical Trials of Human-Identical Milk Oligosaccharides for Infants},
  journal = {Advances in Nutrition},
  year = {2026},
  volume = {17},
  number = {3},
  pages = {100593},
  doi = {10.1016/j.advnut.2026.100593}
}
Kostenlos starten →